NEW HOPE FOR CANADIANS WITH COMMON SEXUAL DIFFICULTIES: Zestra®and UXOR™ Arriving at Canadian Pharmacies in Summer 2015

 As a new study indicates that at least half (50%) of Canadians have had concerns about either their own, or their partner’s, low sexual desire or performance1, two new treatments targeting common sexual difficulties have been approved by Health Canada and are arriving at pharmacies across Canada.

Zestra®, licensed from Innovus Pharmaceuticals (OTCQB: INNV) is ahormone-free medicated topical treatment that improves the local neurosensitivity and increases vasodilation in the vulva, will be available behind the counter at pharmacies beginning June 2015. Two clinical trials published in the Journal ofSex & Marital Therapy established that Zestra® significantly improves a woman’s desire, arousal and sexual satisfaction: 70% of women reported improved sexual satisfaction over multiple uses of the product.

UXOR™, also licensed from Innovus Pharma and sold under the tradename Ejectdelay® in the US, is a mild local anesthetic containing benzocaine that works by desensitizing the nerves in the penis to allow the man to improve control of his climax without detracting from sexual pleasure, will be available at pharmacies at the beginning of August 2015.

The treatments are respectively indicated for two common sexual difficulties:

·         Female Sexual Interest and Arousal Disorder (FSIAD),  a disorder classified in the DSM-5 that is characterized by a lack of sexual interest or arousal and is estimated to affect as many as 4 in 10 women, with the highest prevalence occurring in those between 45 and 64 years of age2.The condition comes with both physical and emotional consequences: women with FSIAD can experience persistent depression and difficulties with their relationships.

·         Premature ejaculation, also known as early ejaculation,rapid ejaculation,rapid climax, and premature climax, which the International Society for Sexual Medicine defines as ejaculation prior to one minute of penetration, or  the inability to delay ejaculation on all, or nearly all, penetrations. Studies show that between adolescence and age 59, approximately 30% of men reported having experienced PE during the previous 12 months3.

Zestra and UXOR have the potential to meet a significant consumer need. As Canadians increasingly prioritize sexual health as being among their primary general health concerns, the opportunity to treat common sexual concerns over-the-counter is significant.

“Orimed is proud to be among the first healthcare companies to not only recognize the credible medical need presented by common sexual difficulties like FSIAD and premature ejaculation, but to also make proven solutions accessible,” said Bernard Fortier, Director of Orimed Pharma Inc. “Sexual health affects a person’s physical and emotional well-being. We encourage Canadians to not only recognize that sexual desire and performance can be legitimate medical concerns, but to talk to their healthcare professionals about the solutions that can best help them achieve optimal sexual health.”

More information visit:
sexforhealth.ca
zestra.ca
uxor.ca
 

About Orimed

Constantly driven forward by innovation, Orimed develops targeted products.  Orimed focuses its efforts in finding solutions that meet physicians’ and their patients’ needs. Orimed is a privatelyowned Canadian pharmaceutical company.

1: Source: A survey of 1531 Canadians was completed online between April 6 and 9, 2015 using Leger’s online panel, LegerWeb. A probability sample of the same size would yield a margin of error of +/- 2.5%, 19 times out of 20.

2: Source: SexualityandU.ca, SexualDysfunction : http://www.sexualityandu.ca/en/health-care-professionals/sexual-dysfunction

3: Source:   Laumann, E.O. et al. (1999). "Sexual Dysfunction in the United States: Prevalence and Predictors". Journal of the American Medical Association281 (6): 537–44. doi:10.1001/jama.281.6.537. PMID 10022110.

For more information:

Maxime-Elisabeth Illick
NATIONAL Public Relations
meillick@national.ca
Phone: 514-843-2322